Need Help With This Product?
Our specialists are here to help you find the best product for your application.
Genetic mutations in amyloid precursor protein (APP) have been found to contribute to the early-onset or prevention of Alzheimer’s disease. The A673T variant of APP, identified via genetic screening of Icelandic and Scandinavian populations, is associated with protection against Alzheimer’s disease, age-related cognitive decline, and amyloid pathology. While the mechanisms of action are not completely understood, the A673T mutation is suggested to decrease its affinity to β-secretase, reduced Aβ production, and a decreased frequency of APP A673T aggregation.
iCell GABANeurons APP A673T were developed as a cellular model to investigate protective effects of this APP variant. The homozygous mutation was engineered into apparently healthy normal induced pluripotent stem cells, followed by differentiation into cortical neurons that exhibit a majority GABAergic phenotype.
Additionally, iCell GABANeuron APP A673V cells with the pathogenic APP variant are ideal for studying early-onset Alzheimer’s disease.
Features of iCell GABANeurons APP A673T:
View all Alzheimer’s disease cell models here.
iCell GABANeurons APP A673T are engineered for an Alzheimer’s disease-associated gene mutation that provides a uniquely relevant biological Alzheimer’s disease model.
Terminally differentiated from human iPS cells, iCell GABANeurons APP A673T are ≥95% pure neuronal population with a majority of GABAergic neurons.
Commercial quantities of consistent GABA phenotype batches ensure reproducible large-scale drug screening programs.
iCell GABANeurons APP A673T are shipped cryopreserved with optimized media. Simply thaw and use.